"I look forward to another incredible two years," Feenstra, the two-term incumbent, said during his five-minute speech at a Tuesday night campaign event that heralded a landslide. His opponent, Ryan ...
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.